Weekly News – October 20

The next shoe to drop:
The Complex Case Panel under scrutiny

Reorgâ€™s Court Opinion Review opinions are not necessarily those of Reorg as a whole.Â

We want to hear from you
Should we dust off our letter from 2022?

and even more fall-out…

Exclusive Content

Find it on Reorg here

Rite Aid files for BK in New Jersey

Forum shopping part deux?

Liability Management 101

Exclusive Content

Find it on CreditSights here

Our take:
This highly sourced research shows a 23% recovery differential for primed lenders & also provides some hope that the pendulum is swinging back to the use of coop agreements.Â
Let us know what you think

FTX clears hurdle

Purdue briefing complete

Oral argument scheduled for December 4, 2023
Find the briefs here

Tons of Macro

10-yr Yield hits 5%

With no relief in sight…

and China isn’t helping

Coming up this week!

This event is available to institutional investors only

Featured Event: Beard Investing Conference

CRC weighs in on Serta

The Academics Speak Up
Purdue Pharma

Purdue Pharma is the gift that keeps on giving. This is our third installment on the twists and turns this case has taken through the Courts. You can read our first installment here, and our second here.

All bets came off the table when the Supreme Court decided to reshuffle the deck by taking on the appeal of the 2nd Circuitâ€™s decision. Not only did SCOTUS take the unusual step of taking on this big ticket issue in BK cases but it also stopped the lower courtâ€™s decision in its tracks putting the breaks on the entire enchilada. We decided to consult with our expert Academic Contributors for our inaugural feature the Academics Speak Up to get their takes on the latest developments.

We are excited to bring you the varying perspectives of Prof. Tony Casey, Prof. Samir Parikh and Prof. Ralph Brubaker.

Read on here, you wonâ€™t be disappointed.

Read more on Purdue Pharma